SironaDx
SironaDx
  • Home
  • Platforms
    • Imaging Mass Cytometry
    • CyTOF Mass Cytometry
    • Next Gen. Sequencing
    • Capillary Electophoresis
    • Quantitative RT- PCR
    • NanoString nCounter
  • Services
    • Services overview
    • IMC/Multiplexed IHC
    • CyTOF Mass Cytometry
    • Human Immune Monitoring
    • Targeted Seq. Panels
    • I-O Expression Assay
    • Oncomine Focus
    • Cancer HSM Panel
    • Disease Sp. Cancer Panels
  • About Us
  • News & Events
  • Contact Us
  • COVID-19 Testing
  • More
    • Home
    • Platforms
      • Imaging Mass Cytometry
      • CyTOF Mass Cytometry
      • Next Gen. Sequencing
      • Capillary Electophoresis
      • Quantitative RT- PCR
      • NanoString nCounter
    • Services
      • Services overview
      • IMC/Multiplexed IHC
      • CyTOF Mass Cytometry
      • Human Immune Monitoring
      • Targeted Seq. Panels
      • I-O Expression Assay
      • Oncomine Focus
      • Cancer HSM Panel
      • Disease Sp. Cancer Panels
    • About Us
    • News & Events
    • Contact Us
    • COVID-19 Testing
  • Home
  • Platforms
  • Services
  • About Us
  • News & Events
  • Contact Us
  • COVID-19 Testing

Oncomine Focus

 

A solid tumor next-generation sequencing assay for biomarker analysis

The Oncomine™ Focus Assay is a targeted, multi-biomarker assay that  enables you to target hotspots, SNVs, indels, CNVs, and gene fusions  from DNA and RNA in a single workflow.

Designed for clinical and translational cancer research, the Oncomine  Focus Assay leverages Ion AmpliSeq™ technology to enable robust  results, low input amounts, and analysis of low quality samples, and is  compatible with FFPE fine needle aspirates and core needle biopsies.


Content

  • Simultaneous detection of hundreds of variants across 52 genes relevant to solid tumors
  • Targets relevant hotspots, SNVs, indels, CNVs, and gene fusions from DNA or RNA in a single workflow
  • Includes solid tumor genes targeted by on-market oncology drugs and published evidence
  • Content driven by the Oncomine™ Knowledgebase, which includes content aligned to approved therapies and indications


Performance

  • Reproducible and sensitive detection of variants across multiple cancer types
  • Compatible with as little as 10 ng sample, including FFPE fine needle biopsies and core needle aspirates
  • Enables results from up to 6 samples per run for DNA and RNA in a single workflow
  • NGS results in days rather than weeks, leveraging Ion Torrent™  sequencing technology and the Ion S5™ System or the Ion PGM™ System
  • Includes Ion Select consumables and reagents manufactured to rigorous standards in our ISO 13485-compliant facility

Copyright © 2019 SironaDx - All Rights Reserved.

Powered by GoDaddy